Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Category: MARA Rating Methodology

Market Access Risk Assessment Company - MARA Rating Company

Patient Population – Who counts, matters

MARA Rating’s Patient Population score (A++–C) predicts HTA approval & reimbursement success. Learn how robust subgroup analysis and real-world evidence drive payer confidence. Too often, M&A teams under-weight market-access risk—patient

Read More »
Market Access Risk Assessment Company - MARA Rating Company

MARA Rating: Our reason to exist

Over the past five years, almost half of drug launches have fallen short of their sales forecasts due to misjudged pricing and reimbursement (P & R) risks, resulting in significant

Read More »